↓ Skip to main content

Advances in Cancer Biomarkers

Overview of attention for book
Cover of 'Advances in Cancer Biomarkers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cancer Biomarkers: A Status Quo
  3. Altmetric Badge
    Chapter 2 Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives
  4. Altmetric Badge
    Chapter 3 Use of Biomarkers in Screening for Cancer.
  5. Altmetric Badge
    Chapter 4 The Role of Metabolomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools
  6. Altmetric Badge
    Chapter 5 The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools.
  7. Altmetric Badge
    Chapter 6 Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development
  8. Altmetric Badge
    Chapter 7 Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects
  9. Altmetric Badge
    Chapter 8 The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects
  10. Altmetric Badge
    Chapter 9 Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
  11. Altmetric Badge
    Chapter 10 Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
  12. Altmetric Badge
    Chapter 11 The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
  13. Altmetric Badge
    Chapter 12 Advances in Cancer Biomarkers
  14. Altmetric Badge
    Chapter 13 Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer
  15. Altmetric Badge
    Chapter 14 The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects
  16. Altmetric Badge
    Chapter 15 CA 19-9: Biochemical and Clinical Aspects.
  17. Altmetric Badge
    Chapter 16 Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
  18. Altmetric Badge
    Chapter 17 Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects
  19. Altmetric Badge
    Chapter 18 Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
  20. Altmetric Badge
    Chapter 19 A Critical Approach to Clinical Biochemistry of Chromogranin A.
  21. Altmetric Badge
    Chapter 20 The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer
  22. Altmetric Badge
    Chapter 21 The Role of CTCs as Tumor Biomarkers
Attention for Chapter 19: A Critical Approach to Clinical Biochemistry of Chromogranin A.
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
A Critical Approach to Clinical Biochemistry of Chromogranin A.
Chapter number 19
Book title
Advances in Cancer Biomarkers
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-94-017-7215-0_19
Pubmed ID
Book ISBNs
978-9-40-177214-3, 978-9-40-177215-0
Authors

Bottoni, Patrizia, De Michele, Teresa, Scatena, Roberto, Patrizia Bottoni, Teresa De Michele, Roberto Scatena

Abstract

Chromogranin A (CGA) is a member of the granin family of proteins which are widespread in endocrine, neuroendocrine, peripheral, and central nervous tissues, where they are typically found in secretory granules. It is well accepted that CGA cooperates to regulate synthesis and secretion of these various granule signaling molecules.Because of its ubiquitous distribution within neuroendocrine tissues, CGA can be a useful diagnostic marker for neuroendocrine neoplasms, including carcinoids, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas (MTC), some pituitary tumors, functioning and nonfunctioning islet cell tumors and other amine precursor uptake and decarboxylation (APUD) tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments. As other tumor markers, it is imperative to know its physiology and pathophysiology, its sensitivity and specificity in different neuroendocrine tumors (NETs), and carefully integrate these data with the clinical data of the single patient, to maximize its diagnostic/prognostic index.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 38%
Student > Ph. D. Student 2 13%
Other 1 6%
Student > Doctoral Student 1 6%
Student > Master 1 6%
Other 2 13%
Unknown 3 19%
Readers by discipline Count As %
Medicine and Dentistry 10 63%
Nursing and Health Professions 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Unknown 4 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2015.
All research outputs
#20,295,501
of 22,832,057 outputs
Outputs from Advances in experimental medicine and biology
#3,969
of 4,951 outputs
Outputs of similar age
#295,893
of 353,176 outputs
Outputs of similar age from Advances in experimental medicine and biology
#189
of 272 outputs
Altmetric has tracked 22,832,057 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,951 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,176 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.